PL397021A1 - Preparat farmaceutyczny do podawania miejscowego - Google Patents
Preparat farmaceutyczny do podawania miejscowegoInfo
- Publication number
- PL397021A1 PL397021A1 PL397021A PL39702103A PL397021A1 PL 397021 A1 PL397021 A1 PL 397021A1 PL 397021 A PL397021 A PL 397021A PL 39702103 A PL39702103 A PL 39702103A PL 397021 A1 PL397021 A1 PL 397021A1
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical formulation
- topical administration
- administering
- inhibitor
- observed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223828 | 2002-05-28 | ||
| EP02011830 | 2002-05-28 | ||
| DE10311613 | 2003-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL397021A1 true PL397021A1 (pl) | 2012-03-26 |
Family
ID=29587313
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL397021A PL397021A1 (pl) | 2002-05-28 | 2003-05-27 | Preparat farmaceutyczny do podawania miejscowego |
| PL372095A PL212134B1 (pl) | 2002-05-28 | 2003-05-27 | Zastosowanie roflumilastu |
| PL372082A PL211870B1 (pl) | 2002-05-28 | 2003-05-27 | Zastosowanie roflumilastu i jego pochodnych w leczeniu zespołu suchego oka oraz oftalmologiczny preparat farmaceutyczny w postaci kropli do oczu |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL372095A PL212134B1 (pl) | 2002-05-28 | 2003-05-27 | Zastosowanie roflumilastu |
| PL372082A PL211870B1 (pl) | 2002-05-28 | 2003-05-27 | Zastosowanie roflumilastu i jego pochodnych w leczeniu zespołu suchego oka oraz oftalmologiczny preparat farmaceutyczny w postaci kropli do oczu |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US20060084685A1 (pl) |
| EP (3) | EP2020243B1 (pl) |
| JP (3) | JP5652983B2 (pl) |
| KR (2) | KR20050014844A (pl) |
| CN (3) | CN101491520B (pl) |
| AT (2) | ATE485821T1 (pl) |
| AU (2) | AU2003240719B2 (pl) |
| BR (2) | BR0311339A (pl) |
| CA (2) | CA2486910C (pl) |
| CY (2) | CY1110312T1 (pl) |
| DE (2) | DE60334692D1 (pl) |
| DK (3) | DK1511516T3 (pl) |
| EA (2) | EA010416B1 (pl) |
| ES (3) | ES2354971T3 (pl) |
| HK (2) | HK1079437A1 (pl) |
| HR (1) | HRP20041211B1 (pl) |
| HU (1) | HUE039709T2 (pl) |
| IL (3) | IL164935A (pl) |
| IS (1) | IS2639B (pl) |
| LT (1) | LT2020243T (pl) |
| MA (1) | MA27813A1 (pl) |
| ME (1) | ME00565A (pl) |
| MX (2) | MXPA04011528A (pl) |
| NO (2) | NO334882B1 (pl) |
| NZ (3) | NZ553731A (pl) |
| PL (3) | PL397021A1 (pl) |
| PT (3) | PT1511516E (pl) |
| RS (1) | RS51104B (pl) |
| SI (2) | SI2020243T1 (pl) |
| TR (1) | TR201815573T4 (pl) |
| UA (2) | UA81910C2 (pl) |
| WO (2) | WO2003099334A1 (pl) |
| ZA (2) | ZA200408649B (pl) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| CN101491520B (zh) * | 2002-05-28 | 2011-03-16 | 尼科梅德有限责任公司 | 局部应用的药物制剂 |
| KR20050057175A (ko) | 2002-09-20 | 2005-06-16 | 알콘, 인코퍼레이티드 | 안구건조증 치료용 사이토카인 합성 저해제의 용도 |
| FR2851247B1 (fr) * | 2003-02-19 | 2007-06-29 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
| MXPA04008070A (es) | 2003-03-10 | 2004-11-26 | Altana Pharma Ag | Novedoso proceso para la preparacion de roflumilasto. |
| JP2007517893A (ja) * | 2004-01-10 | 2007-07-05 | バイオリピッド インコーポレイテッド | 脂質組成物及び該脂質組成物の使用方法 |
| DE102004046236A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| EP1874308A1 (en) * | 2005-03-08 | 2008-01-09 | Nycomed GmbH | Roflumilast for the treatment of diabetes mellitus |
| JP5383183B2 (ja) * | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストを含有する矯味された剤形 |
| KR20080029974A (ko) * | 2005-06-09 | 2008-04-03 | 산텐 세이야꾸 가부시키가이샤 | 로플루밀라스트 점안액 |
| CA2637573C (en) | 2006-02-21 | 2013-07-02 | Eisai R&D Management Co., Ltd. | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives |
| AU2008215411B2 (en) | 2007-02-16 | 2012-11-22 | Eisai R & D Management Co., Ltd. | Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid |
| ATE538102T1 (de) | 2007-08-17 | 2012-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung eines chinazolinderivats |
| WO2009025239A1 (ja) | 2007-08-17 | 2009-02-26 | Eisai R & D Management Co., Ltd. | 新規外用剤 |
| RU2012122169A (ru) | 2009-10-30 | 2013-12-10 | Нестек С.А. | Способы поддержания здоровья глаз и облегчения глазных болезней у псовых |
| ES2377785B2 (es) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento del ojo seco. |
| ES2408132B1 (es) * | 2010-09-08 | 2014-04-04 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento de la epífora. |
| EP2683376B1 (en) * | 2011-03-07 | 2018-11-28 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
| CN102793684B (zh) * | 2011-05-26 | 2016-02-17 | 杭州赛利药物研究所有限公司 | 罗氟司特液体制剂及其制备方法 |
| WO2013000917A1 (en) * | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing regorafenib |
| WO2013155123A1 (en) * | 2012-04-10 | 2013-10-17 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of cyld |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| CN103570610B (zh) * | 2012-07-18 | 2017-08-11 | 重庆华邦制药有限公司 | 一种罗氟司特微粒的制备方法 |
| CN111904962A (zh) | 2012-11-08 | 2020-11-10 | 理森制药股份公司 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
| WO2015022418A1 (en) | 2013-08-16 | 2015-02-19 | Takeda Gmbh | Treatment of cognitive impairment with pde4 inhibitor |
| CN105434328A (zh) * | 2014-09-01 | 2016-03-30 | 天津药物研究院有限公司 | 一种含罗氟司特固体分散体的固体制剂及其制备方法 |
| EP3210974B1 (en) * | 2014-10-24 | 2020-01-29 | Hisamitsu Pharmaceutical Co., Inc. | Prodrug of roflumilast |
| CN104997959A (zh) * | 2015-08-21 | 2015-10-28 | 蔡宇平 | 一种用于治疗睑板腺囊肿的中药 |
| CN106148528B (zh) * | 2016-07-11 | 2019-10-01 | 赵晨 | 一种遗传性Usher综合征的致病突变及其检测试剂 |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| CN108283620A (zh) * | 2018-03-13 | 2018-07-17 | 兆科药业（广州）有限公司 | 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法 |
| KR20210044191A (ko) | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
| KR102117525B1 (ko) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물 |
| MX2022009399A (es) | 2020-01-31 | 2022-09-19 | Arcutis Biotherapeutics Inc | Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica. |
| AU2021268977B2 (en) * | 2020-05-07 | 2024-05-23 | Arcutis Biotherapeutics, Inc. | Treatment of skin conditions using high Krafft temperature anionic surfactants |
| WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| AU2022218993A1 (en) * | 2021-02-10 | 2023-08-03 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| CA3221045A1 (en) * | 2021-06-01 | 2022-12-08 | Andres Garcia | Extended release drug delivery system for ocular drugs and methods of use |
| AU2022353032A1 (en) * | 2021-09-22 | 2024-03-28 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753945A (en) * | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US5011843A (en) * | 1988-05-31 | 1991-04-30 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
| US5891904A (en) * | 1992-09-14 | 1999-04-06 | Wolf-Georg Forssmann | Use of inhibitors of phosphodiesterase IV |
| KR100331255B1 (ko) * | 1993-07-02 | 2002-10-25 | 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 | 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도 |
| US5747069A (en) * | 1993-08-10 | 1998-05-05 | Fujisawa Pharmaceutical Co., Ltd. | Percutaneously absorbable preparation |
| ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
| KR20010075287A (ko) * | 1998-09-29 | 2001-08-09 | 후지야마 아키라 | 피리도피라진 화합물의 신규한 염 및 그의 결정 |
| US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
| US20020006418A1 (en) * | 1998-10-13 | 2002-01-17 | John Kung | Composition to enhance permeation of topical skin agents |
| AU3284000A (en) | 1999-03-10 | 2000-09-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis |
| US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| AR026254A1 (es) * | 1999-10-29 | 2003-02-05 | Smithkline Beecham Plc | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 |
| US6740655B2 (en) * | 2000-01-31 | 2004-05-25 | Pfizer Inc | Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes |
| WO2001060358A1 (en) * | 2000-02-16 | 2001-08-23 | University Of Nebraska Medical Center | Method and compositions for treating fibrotic diseases |
| AU2001261962B2 (en) * | 2000-05-25 | 2005-04-21 | Merck Frosst Canada Ltd | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
| WO2002038155A1 (en) * | 2000-11-07 | 2002-05-16 | Merck & Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20030092706A1 (en) * | 2001-11-09 | 2003-05-15 | Johannes Barsig | Combination |
| CN101491520B (zh) * | 2002-05-28 | 2011-03-16 | 尼科梅德有限责任公司 | 局部应用的药物制剂 |
-
2003
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/en not_active Expired - Lifetime
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Application Discontinuation
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 EP EP03755048A patent/EP1511516B1/en not_active Expired - Lifetime
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active IP Right Cessation
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en active Application Filing
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 EP EP03730122A patent/EP1511481B1/en not_active Expired - Lifetime
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en active Application Filing
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
-
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
- 2004-12-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
-
2005
- 2005-12-14 HK HK05111481.8A patent/HK1079437A1/xx not_active IP Right Cessation
- 2005-12-16 HK HK05111628.2A patent/HK1079445A1/xx not_active IP Right Cessation
-
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
-
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
-
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
-
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
-
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
-
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
-
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL397021A1 (pl) | Preparat farmaceutyczny do podawania miejscowego | |
| AU1708202A (en) | Organic compounds | |
| WO2001082897A3 (en) | Liposome drug delivery | |
| WO2002024203A3 (en) | Controlled release formulations for oral administration | |
| MY145885A (en) | Controlled release formulations for oral administration |